-ALX-0171 is a Potential First-in-Class Therapy-
-Tremendous Potential in Multiple Lung Diseases-
Report is Available for Download at: www.lifesciadvisors.com/clients/ablynx
Ablynx NV (Euronext Brussels: ABLX) just reported successful Phase 1 results for ALX-0171, the first inhaled nanobody. Delivering therapeutic antibodies to the lung via inhalation has proven unsuccessful due to serious immunogenicity concerns. In this study, ALX-0171 was well tolerated and did not exhibit any immunogenicity effects typically associated with antibodies.
Phase 1 Data Provides Proof-of-Concept for Inhaled Nanobodies. Ablynx just reported Phase 1 data that suggests that ALX-0171 could be successfully administered directly into the lung in a clinical trial setting. This confirms its potential as a first-in-class therapy to treat RSV infections. More importantly, this confirms the potential for the Nanobody platform to develop therapeutic compounds that can be delivered directly into the lung. Beyond RSV, the ability to deliver Nanobodies directly to the lung has broad implications for the potential of Ablynx’s platform to generate Nanobodies treating a variety of lung diseases, including Asthma and COPD. These potential implications address very large market opportunities that Ablynx could be poised to benefit from.
ALX-0171, is a trivalent molecule specifically designed by Ablynx for direct lung delivery via nebulizer to treat respiratory syncytial virus (RSV) infections. The specific structure of the Nanobody lends a small size, robustness, and stability that makes it possible for direct lung delivery. Direct lung delivery is a more convenient route of administration for treating a variety of lung diseases that scientists have not been able to successfully achieve with antibodies.